Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIRT 1696 BS in healthy subjects
NCT02254096Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2002
- Primary completion
- Jul 2002
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of BIRT-1696-BS in psoriasis (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of subjects with adverse events at 44 days, Number of subjects with clinically significant changes in vital signs at 44 days and 4 more. Started May 2002; status: completed.
02
Drugs
BIRT-1696-BS
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT02254096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02254096.